BD Losing a Segment President to Retirement

BD (Becton, Dickinson and Company) today announced that Dr. Michael (Mike) Garrison will retire this fall after more than 20 years with the company. His departure date is slated for Oct. 2.

Garrison is currently executive vice president and president of BD’s Medical Essentials and BioPharma Systems segments. During his tenure, Garrison held several leadership roles, including executive vice president and president of BD’s Medical segment, worldwide president of Medication Management Solutions, and worldwide president of Surgery. Before joining BD in 2005, Garrison held various roles across R&D and marketing within the medtech industry.

“Mike has made a significant impact on BD over the past two decades, helping guide our company through periods of transformation while always keeping our customers, patients and associates at the center of his decisions,” BD Chairman/President/CEO Tom Polen said. “He has built strong teams, developed exceptional leaders and helped position our business for the future. We are grateful for Mike’s leadership, partnership and many contributions to BD, and we wish him well in his retirement.”

Garrison will remain in his role through the end of the fiscal year (Sept. 30). A comprehensive search is underway to identify the next president of Medical Essentials. Going forward, BioPharma Systems will report directly to Polen, streamlining the operating model and reflecting the segment’s strategic importance as a growth driver.

“It has been a privilege to spend more than two decades at BD, working alongside talented teams who are deeply committed to improving healthcare around the world,” Garrison stated. “I will always value the people, purpose, and impact that have made my time at BD so meaningful, and I look forward to seeing the company continue to advance the future of care.”

BD is one of the world’s largest pure-play medical technology companies that is driving innovation across medical essentials, connected care, biopharma systems, and interventional. The company develops technologies, services, and solutions that optimize clinical operations and improve care for patients. Operating across the globe, with more than 60,000 employees, BD delivers billions of products annually. By working in close collaboration with customers, BD can help enhance outcomes, lower costs, increase clinical efficiency, improve safety, and expand access to healthcare.